Shanghai Institute of Hypertension
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1958-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.china-sih.com/
Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension
Not Applicable
Not yet recruiting
- Conditions
- Chronic Kidney Disease(CKD)Nocturnal Hypertension
- Interventions
- Drug: Antihypertensive treatment with Arotinolol or Amlodipine or ClonidineDrug: Placebo-controlled group
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Shanghai Institute of Hypertension
- Target Recruit Count
- 200
- Registration Number
- NCT06780865
Home Blood Pressure Intervention in the Community Trial
Not Applicable
Recruiting
- Conditions
- Home Blood Pressure
- Interventions
- Drug: Intensive Home BP controlDrug: Standard Home BP control
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Shanghai Institute of Hypertension
- Target Recruit Count
- 10000
- Registration Number
- NCT05858944
- Locations
- 🇨🇳
Community hospitals, Shanghai, Shanghai, China
Registry Study on "Control Nocturnal Hypertension to Reach the Target "
Recruiting
- Conditions
- Nocturnal Hypertension
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Shanghai Institute of Hypertension
- Target Recruit Count
- 4500
- Registration Number
- NCT04137549
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Placebo of Gastrodia and Uncaria granule
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Shanghai Institute of Hypertension
- Target Recruit Count
- 605
- Registration Number
- NCT04035824
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Shanghai Institute of Hypertension
- Target Recruit Count
- 400
- Registration Number
- NCT02156024
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Amlodipine Plus/Minus Atorvastatin for Protection of Arteries
Phase 4
- Conditions
- Arterial and Arteriolar Disorders
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Shanghai Institute of Hypertension
- Target Recruit Count
- 109
- Registration Number
- NCT01922687
- Locations
- 🇨🇳
Shanghai Institute of Hypertension, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath